Novo Nordisk/$NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Bagsvaerd, Denmark
Employees
77,406
ISIN
US6701002056
Website
Novo Nordisk Metrics
BasicAdvanced
$309B
18.87
$3.69
0.21
$1.18
2.35%
Price and volume
Market cap
$309B
Beta
0.21
52-week high
$143.49
52-week low
$57.00
Average daily volume
8.8M
Dividend rate
$1.18
Financial strength
Current ratio
0.739
Quick ratio
0.542
Long term debt to equity
69.518
Total debt to equity
85.696
Dividend payout ratio (TTM)
48.61%
Interest coverage (TTM)
41.95%
Profitability
EBITDA (TTM)
24,423.225
Gross margin (TTM)
84.65%
Net profit margin (TTM)
34.51%
Operating margin (TTM)
48.43%
Effective tax rate (TTM)
20.93%
Revenue per employee (TTM)
$616,530
Management effectiveness
Return on assets (TTM)
23.29%
Return on equity (TTM)
88.12%
Valuation
Price to earnings (TTM)
18.873
Price to revenue (TTM)
6.503
Price to book
14.2
Price to tangible book (TTM)
67.45
Price to free cash flow (TTM)
26.51
Free cash flow yield (TTM)
3.77%
Free cash flow per share (TTM)
262.88%
Dividend yield (TTM)
1.70%
Forward dividend yield
2.35%
Growth
Revenue change (TTM)
24.11%
Earnings per share change (TTM)
17.93%
3-year revenue growth (CAGR)
26.70%
10-year revenue growth (CAGR)
12.46%
3-year earnings per share growth (CAGR)
29.74%
10-year earnings per share growth (CAGR)
15.18%
3-year dividend per share growth (CAGR)
29.91%
10-year dividend per share growth (CAGR)
16.38%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Bulls say / Bears say
Novo Nordisk's experimental obesity drug, amycretin, demonstrated superior weight loss results in early trials, with participants losing an average of 24.3% of their body weight on the highest dose, surpassing current market leaders. (ft.com)
The company has submitted an application to the European Medicines Agency for a higher dose of its obesity treatment, Wegovy, after clinical trials showed one in three participants achieved a weight loss of 25% or more. (reuters.com)
Novo Nordisk raised its full-year sales and operating profit outlook for the third time in 2023, reflecting strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States. (investing.com)
Novo Nordisk's shares have fallen 27% in March 2025, marking its worst month since 2002, due to concerns over slowing growth for its obesity drug Wegovy and competition from Eli Lilly's Zepbound. (bloomberg.com)
The company ousted CEO Lars Fruergaard Jørgensen amid concerns that it is losing its first-mover advantage in the competitive obesity drug market, with shares down 32% year-to-date and 59% from their peak. (investing.com)
Novo Nordisk misjudged the U.S. market demand for its weight-loss drug Wegovy, leading to supply shortages and high out-of-pocket costs for patients, allowing competitors like Eli Lilly to gain market share. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health
CNBC Television·1 day ago
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
CNBC·1 day ago
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
CNBC·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $309B as of July 10, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 18.87 as of July 10, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of July 10, 2025, the dividend rate is $1.1814 and the yield is 2.35%. Novo Nordisk has a payout ratio of 48.61% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.